Status:
COMPLETED
Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Cognitive Aging
Eligibility:
All Genders
75+ years
Phase:
NA
Brief Summary
This proposal aims to determine whether low does of the alpha-2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy elderly subjects.
Detailed Description
Primary: * To determine whether low does of the α2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated working memory and executive control functions, in healthy elderly su...
Eligibility Criteria
Inclusion
- Subjects enrolled will be nondemented, male and female individuals who meet the following inclusion criteria:
- 75 years of age or older
- Fluent in English
- Stable medical condition for at least 4 weeks prior to Screening visit
- Stable dose of non-excluded medications for at least 4 weeks prior to Screening visit
Exclusion
- Dementia
- Mild Cognitive Impairment (Amnestic MCI)
- Clinically significant neurologic disease
- Clinically significant or unstable medical conditions that would interfere with participation in the trial
- Known hypersensitivity to guanfacine
- History of alcohol or substance abuse or dependence within the past 5 years
- Active major psychiatric disorders, including major depression
- History of mental retardation
- Significant abnormalities on clinical laboratories, ECG, or physical examination
- Impairment of visual or auditory acuity sufficient to interfere with completion of study procedures
- Education level \< 6 years
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT00935493
Start Date
June 1 2009
End Date
August 1 2012
Last Update
August 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alzheimer's Disease Research Unit, Yale University School of Medicine
New Haven, Connecticut, United States, 06510